文献速递胸部肿瘤

一线铂类联合化疗后维持舒尼替尼治疗晚期IIIB/IV期非小细胞肺癌:随机双盲安慰剂对照III期研究CALGB 30607(Alliance)

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
PubMed 文献 · J Thorac Oncol · 2017-02-01

CALGB 30607是一项随机双盲安慰剂对照III期研究,纳入一线铂类双药化疗(联合或不联合贝伐珠单抗)4周期后无进展的IIIB/IV期NSCLC患者210例,随机接受舒尼替尼37.5 mg/d或安慰剂维持治疗。舒尼替尼组中位无进展生存期4.3个月 vs 安慰剂组2.6个月(HR=0.62,95%CI 0.47-0.82,P=0.0006),中位总生存期11.7个月 vs 12.1个月(HR=0.98,95%CI 0.73-1.31,P=0.89)。结论认为维持舒尼替尼安全并改善PFS,但对总生存无影响,该背景下无进一步研究舒尼替尼的空间。

要点

  • 舒尼替尼维持治疗较安慰剂改善PFS:中位4.3个月 vs 2.6个月,HR=0.62(95%CI 0.47-0.82,P=0.0006)。
  • 总生存无显著差异:中位11.7个月 vs 12.1个月,HR=0.98(95%CI 0.73-1.31,P=0.89)。
  • 舒尼替尼组3/4级不良事件包括乏力25%、血小板减少12%、高血压12%等,安慰剂组无3/4级不良事件。

核心结论

  • 维持舒尼替尼在IIIB/IV期NSCLC中安全并改善PFS,但对总生存无影响,作者认为该背景下无进一步研究舒尼替尼的空间。

研究设计与样本

  • CALGB 30607(Alliance)为随机、双盲、安慰剂对照III期研究,纳入一线铂类双药化疗(联合或不联合贝伐珠单抗)4周期后无进展的IIIB/IV期NSCLC患者,贝伐珠单抗仅允许在4周期化疗期间使用。
  • 患者随机接受舒尼替尼37.5 mg/d或安慰剂,治疗至不可接受的不良事件、进展或死亡;主要终点为无进展生存期(PFS)。
  • 共210例患者入组、随机并纳入意向性分析,其中10例未接受维持治疗(安慰剂组4例,舒尼替尼组6例)。

主要发现

  • 舒尼替尼组中位PFS为4.3个月,安慰剂组为2.6个月(HR=0.62,95%CI 0.47-0.82,P=0.0006)。
  • 舒尼替尼组中位总生存期为11.7个月,安慰剂组为12.1个月(HR=0.98,95%CI 0.73-1.31,P=0.89)。
  • 舒尼替尼组发生率超过5%的3/4级不良事件包括乏力(25%)、血小板减少(12%)、高血压(12%)、皮疹(11%)、黏膜炎(11%)、中性粒细胞减少(7%)和贫血(6%),安慰剂组无3/4级不良事件。
  • 舒尼替尼组发生3例5级事件(1例肺出血、1例其他肺部事件、1例未关联常见不良事件术语标准的死亡),安慰剂组发生2例5级事件(1例其他肺部事件、1例血栓栓塞)。

临床怎么用

  • 作者结论认为维持舒尼替尼在IIIB/IV期NSCLC中安全并改善PFS,但对总生存无影响,且该背景下无进一步研究舒尼替尼的空间。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The aim of this study was to evaluate efficacy of maintenance sunitinib after first-line chemotherapy for stage IIIB/IV NSCLC. METHODS: Cancer and Leukemia Group B 30607 trial was a randomized, double-blind, placebo-controlled, phase III study that enrolled patients without progression after four cycles of first-line platinum-based doublet chemotherapy with or without bevacizumab. Bevacizumab was allowed only during the four cycles of chemotherapy. Patients were randomized to receive sunitinib, 37.5 mg/d, or placebo and were treated until unacceptable adverse event(s), progression, or death. The primary end point was progression-free survival (PFS). RESULTS: A total of 210 patients were enrolled, randomized, and included in the intent-to-treat analysis. Ten patients did not receive maintenance therapy (four who received placebo and six who received sunitinib). Grade 3/4 adverse events affecting more than 5% of the patients were fatigue (25%), thrombocytopenia (12%), hypertension (12%), rash (11%), mucositis (11%), neutropenia (7%), and anemia (6%) for sunitinib and none for placebo. There were three grade 5 events in patients receiving sunitinib (one pulmonary hemorrhage, one other pulmonary event, and one death not associated with a Common Terminology Criteria for Adverse Events term) and two grade 5 events in patients receiving placebo (one other pulmonary event and one thromboembolism). Median PFS was 4.3 months for sunitinib and 2.6 months for placebo (hazard ratio = 0.62, 95% confidence interval: 0.47-0.82, p = 0.0006). Median overall survival was 11.7 months for sunitinib versus 12.1 months for placebo (hazard ratio = 0.98, 95% confidence interval: 0.73-1.31, p = 0.89). CONCLUSIONS: Maintenance sunitinib was safe and improved PFS as maintenance therapy in stage IIIB/IV NSCLC but had no impact on overall survival. There is no room for future investigations of sunitinib in this setting.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Baggstrom MQ, Socinski MA, Wang XF, et al. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance). J Thorac Oncol. 2017. PMID: 28161554. doi:10.1016/j.jtho.2017.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。